Abstract This study is the first to analyse real-world use of Auvelity (dextromethorphan HBr and bupropion HCL, 45 mg/105 mg extended-release tablets) for treating major depressive disorder (MDD) in the United States. Researchers reviewed medical records of over 22,000 adults, examining factors like age, gender, insurance, and previous depression treatments. Findings revealed that patients...
Journal of Affective DisordersDecember 17, 2025Faheem Ahmed Khan, Nuruliarizki Shinta Pandupuspitasari, Tewin Tencomnao et al.2 citations
Psilocybin, a naturally occurring hallucinogenic substance present in certain mushrooms, has drawn growing attention as a therapeutic breakthrough for several mental and psychiatric conditions. Psilocybin originated in spiritual and cultural traditions and has become the focus of extensive scientific research. This meta-analysis and systematic review aggregate results from the literature to...
Introduction: Major depressive disorder (MDD) affects over 21 million adults in the U.S (NIMH, 2023) and remains a significant public health challenge. Despite the effectiveness of traditional medications, 30% of patients remains resistant. Little is known about the beliefs individuals hold regarding novel treatments, such as psilocybin and the motivations behind medication acceptance. This...
The contemporary global mental health crisis—marked by rising rates of depression, chronic stress, and social disconnection—calls for approaches that integrate biological, psychological, social, and spiritual dimensions of human well-being. This study revisits the biopsychological framework of Abū Zayd al-Balkhī (850–934 CE), articulated in Maṣāliḥ al-Abdān wa al-Anfus, to assess its relevance...
Depression is one of the most prevalent and burdensome mental health conditions worldwide, affecting millions and contributing to over 700,000 deaths by suicide annually. Nearly half of patients with major depressive disorder fail to respond adequately to standard antidepressant treatments such as selective serotonin reuptake inhibitors (SSRIs). Psilocybin-assisted therapy (PAT) has emerged as...
Objective: To compare acceptability and effectiveness of psilocybin, ketamine and commonly prescribed antidepressants in the management of Major Depressive Disorder (MDD). Methods: This is a systematic review with network meta-analysis. The survey was conducted between January and June 2023, employing MEDLINE, PsyINFO, Embase, Web of Science and ClinicalTrials.gov databases. Randomized...
Abstract Psilocybin has demonstrated promising antidepressant effects in depression and treatment-resistant depression (TRD) in controlled clinical trials. However, its effectiveness and safety in real-world therapeutic settings remain largely unknown. Although psilocybin is not yet approved as an antidepressant treatment, Switzerland’s unique legal framework allows its limited medical use for...
Individuals with eating disorders (EDs) have an increased risk of treatment resistant depression (TRD) and treatment resistant bipolar disorder (TRBD) and a higher rate of suicidal ideation and death by suicide than individuals without EDs. Individuals with EDs are less responsive to conventional treatments for mood disorders than individuals without EDs. Ketamine has evidence for treatment of...
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental health conditions, notably depression, loneliness, and existential distress. Traditional pharmacological treatments often exhibit limited efficacy and poor tolerability in older patients, primarily due to age-related physiological changes and the...
NPJ Digital MedicineDecember 8, 2025Joseph Geraci, Bessi Qorri, Mike Tsay et al.
Clinical trial failures are frequently driven by patient heterogeneity and limited sample sizes that obscure treatment effects by diluting statistical power. We introduce NetraAI, a novel explainable artificial intelligence (AI) platform that integrates dynamical-systems modeling, evolutionary long-range memory feature selection, and large-language model (LLM)-generated insights, to discover...
Introduction: About 30% of depressed patients suffer from a protracted course in which the disorder continues to cause significant burden despite treatment efforts. While originally developed for relapse prevention, mindfulness-based cognitive therapy (MBCT) has increasingly been investigated in depressed patients with such 'difficult-to-treat' courses. This is a protocol for an individual...
Major Depressive Disorder (MDD), particularly its treatment-resistant form, represents a substantial burden on global public health, characterized by low remission rates with conventional monoaminergic pharmacotherapy. The paradigm shift toward glutamatergic modulation has identified the N-methyl-D-aspartate (NMDA) receptor as a critical target for rapid-acting antidepressants. Nitrous oxide...
In general, ischemic stroke patients experience psychological problems anxiety, depression and increased blood pressure to be above normal. The purpose of the study was to analyze anxiety, depression and blood pressure post mindfulness spiritual intervention combination breathing exercise. Quasy experiment research design with a large sample of 25 respondents through purposive sampling...
Ketamine may be a viable treatment option for patients with treatment-resistant post-stroke depression. Further research is warranted to better understand the efficacy and safety of ketamine in this specific patient population.
Background: Depressive disorders affect approximately 280 million globally, with many finding treatments ineffective or limited by side effects. Growing evidence suggests that psychedelic therapies may help alleviate depressive symptoms. Among these, lysergic acid diethylamide (LSD) microdosing shows promise for major depressive disorder (MDD). However, research on LSD microdosing in clinical...
The rising incidence of depression and anxiety among the elderly is a growing public health concern. While pharmacological treatments are widely used, they often present challenges such as side effects and dependency, highlighting the need for evidence-based psychotherapeutic alternatives. Mindfulness-Based Cognitive Behavioral Therapy (MBCBT) integrates mindfulness techniques with cognitive...
Depression is prevalent among older adults in Southeast Asia, with fear of death as a key contributing factor. In Thailand, Buddhist death contemplation practices promote acceptance of mortality and may support mental well-being. However, their impact on mental health among elderly Thai Buddhist meditation practitioners remains underexplored. The aim of this study was to examine the...
Depression remains a global public health challenge, prompting interest in translational targets which allow for more effective and rapidly acting interventions. Nitrous oxide (N2O), an N-methyl-d-aspartate receptor antagonist, has demonstrated potential as a rapid-acting antidepressant. This study synthesised existing data on the efficacy and safety of N2O in depressive disorders. We...
JAACAP openDecember 1, 2025Tram N B Nguyen, Benjamin A Ely, Aria Vitale et al.
Youth with depression use cannabis at high rates, and exposure to cannabinoids in adolescence has been shown to deleteriously alter the reward system. However, there has been sparse research on the link between adolescent cannabis use and anhedonia, a core symptom of depression and clinical manifestation of reward dysfunction. Here, in a sample of adolescents presenting predominantly with mood...
Treatment-resistant depression (TRD) is a complex and heterogeneous condition affecting a considerable subset of patients who do not respond to conventional antidepressants. Given the limitations of traditional treatment strategies, there is a growing need for alternative and personalized approaches. This review explores the neurobiological underpinnings of TRD and examines the efficacy of...